反応式
[F:1][C:2]1[CH:7]=[CH:6][C:5]([C@H:8]([CH2:18][C:19]([N:21]2[CH2:26][CH2:25][O:24][CH2:23][CH2:22]2)=[O:20])[C:9]([NH:11][C@H:12]([CH:16]=O)[CH:13]([CH3:15])[CH3:14])=[O:10])=[CH:4][CH:3]=1.[NH2:27][C:28]1[CH:29]=[CH:30][C:31]([O:34][CH3:35])=[N:32][CH:33]=1.C(O)(=O)C.C([BH3-])#N.[Na+]>CO>[F:1][C:2]1[CH:7]=[CH:6][C:5]([C@H:8]([CH2:18][C:19]([N:21]2[CH2:26][CH2:25][O:24][CH2:23][CH2:22]2)=[O:20])[C:9]([NH:11][C@H:12]([CH2:16][NH:27][C:28]2[CH:33]=[N:32][C:31]([O:34][CH3:35])=[CH:30][CH:29]=2)[CH:13]([CH3:14])[CH3:15])=[O:10])=[CH:4][CH:3]=1参加物
反応物 4
生成物 1
試薬・触媒・溶媒 1
実験手順
2-(S)-(4-Fluoro-phenyl)-N-(1-(S)-formyl-2-methyl-propyl)-4-morpholin-4-yl-4-oxo-butyramide (350 mg, 0.96 mmol, 1.0 eq.) and 5-Amino-2-methoxy-pyridine (240 μL, 1.92 mmol, 2.0 eq.) dissolved in MeOH (2.5 mL) and acetic acid (106 mL, 1.92 mmol, 2.0 eq.) added via syringe at room temperature. Sodium cyanoborohydride (121 mg, 1.92 mmol, 2.0 eq.) added in portion and the reaction monitored the reaction by LC/MS. Upon completion, solvents were evaporated and dissolved in EtOAc (100 mL) washed with brine, dried over MgSO4, filtered and evaporated. Purification by preparative mass-directed HPLC provided the title compound as a white solid after evaporation and lyophilization (2.6 mg, 5.6 □mol, 0.6%). HPLC-MS calcd. for C25H33FN4O4 (M+H+) 473.3, found 473.5.
後処理
- customthe reaction by LC/MS
- customUpon completion, solvents were evaporated
- dissolutiondissolved in EtOAc (100 mL)
- washwashed with brine
- dry with materialdried over MgSO4
- filtrationfiltered
- customevaporated
- customPurification by preparative mass-directed HPLC
出典と根拠
- ORDレコード
- ord-950430614803451d89e67ca6730e7c21
- 出典データセット
- uspto-grants-2009_03
- 特許番号
- US07501408B2
関連ノート
読み込み中…